SCHEMBL444623

SCHEMBL444623

Cc1noc(CN)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL12478390 0.98
SCHEMBL474898 0.81
Hydrochloric Acid SCHEMBL475088 0.79 HTR1A (0.44)
SCHEMBL5766231 0.78 MAPT (0.43)
SCHEMBL12309 0.77
SCHEMBL6676822 0.76 HTR1A (0.52)
SCHEMBL13593973 0.75
Ammonia Solution, Strong SCHEMBL3447928 0.75
SCHEMBL3256199 0.75
SCHEMBL8128674 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255109-A1 Non-peptide GnRH antagonists VANTIA, LTD 2008-10-16 US claimed
US-7365065-B2 Non-peptide GnRH antagonists FERRING B.V. (NL) 2008-04-29 US claimed
EP-1485356-A1 NON-PEPTIDE GnRH ANTAGONISTS Ferring BV (NL) 2004-12-15 EP claimed
WO-2003078398-A1 NON-PEPTIDE GnRH ANTAGONISTS FERRING BV (NL) 2003-09-25 WO claimed
US-12116343-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-10-15 US disclosed
WO-2023205415-A1 TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF MITOBRIDGE INC. (US) 2023-10-26 WO disclosed
WO-2023154344-A1 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 WO disclosed
US-20220340523-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2022-10-27 US disclosed
EP-3083619-B1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES LLC (US) 2021-11-03 EP disclosed
WO-2021154997-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-08-05 WO disclosed
US-10828281-B2 Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) 2020-11-10 US disclosed
EP-3193880-B1 INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL LILLY CO ELI (US) 2020-03-25 EP disclosed
US-20050222139-A1 Non-peptide gnrh antagonists FERRING B.V. (NL) 2005-10-06 US disclosed
EP-1485356-A1 NON-PEPTIDE GnRH ANTAGONISTS Ferring BV (NL) 2004-12-15 EP disclosed
WO-2003078398-A1 NON-PEPTIDE GnRH ANTAGONISTS FERRING BV (NL) 2003-09-25 WO disclosed
US-5288732-A Fungicides for plants BAYER AKTIENGESELLSCHAFT (DE) 1994-02-22 US disclosed
US-5231109-A Fungicides BAYER AKTIENGESELLSCHAFT (DE) 1993-07-27 US disclosed
EP-0259737-B1 2-CYANO-2-ALKOXIMINO-ACETAMIDE BAYER AG (DE) 1992-11-25 EP disclosed
US-4886833-A FUNGICIDES, PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 1989-12-12 US disclosed
EP-0259737-A2 2-Cyano-2-alkoximino-acetamide BAYER AG (DE) 1988-03-16 EP disclosed